Kornimate/medical-research-clean huggingface dataset:
hypoxemia in infants after palliative surgery

Conditions: Congenital Disorders

Summary: congenital heart disease is a major cause of morbidity and mortality in infants. many cardiac defects require surgical palliation or repair in the newborn period. the effects of chronic hypoxia on growth and development are unclear. infants with very severe cardiac defects may undergo surgery in infancy, but often this cardiac surgery can provide only palliation, not correction. as a result, these infants are exposed to a physiology of chronic hypoxia during the neonatal period through infancy, a critical period of growth and development. the optimal oxygen saturations for infants with palliated cardiac defects is unknown. the purpose of this study is to analyze the growth and development of infants with post-surgical palliation in infancy and assess variations in oxygenation saturations and hemodynamics as they relate to weight gain, linear growth and increases in head circumference during the first three years of life.

we wish to do a retrospective review of clinical data on infants who have undergone surgical palliation for the following cardiac defects over the past five years (from january 1, 2001 through march 31, 2006): hypoplastic left heart syndrome pulmonary atresia severe pulmonary stenosis. the patient charts, between the dates of 01.01.2001and 03.31.2006, will be reviewed from children's healthcare of atlanta, egleston hospital and the sibley heart center cardiology clinics of children's healthcare of atlanta. we will review approximately 180 charts. we will collect the following information on each patient: medical record number account number dates of admission, discharge, treatment or death, date of birth information regarding cardiac signs and symptoms, medication information age, weight , diagnoses and results of imaging studies clinic visit information during routine follow up appointments such as weight, length, head circumference, oxygen saturations, vital signs, medications, diet, blood pressures, symptoms,blood tests, chest x-ray findings, dates and types of procedures readmissions, feeding regimen, cardiac catheterization data, surgical data parent histories of developmental milestones, physical therapy and speech therapy consultations, feeding history, evaluations of swallowing function airway symptoms noncardiac procedures and noncardiac medical problems family history and social history as it relates to care of the infants at home, complications of medical or surgical treatment and cerebral oximetry.

Eligibility criteria:
inclusion criteria: * patient charts from 01/01/2001 through 03/31/2006 seen at children's healthcare of atlanta or sibley heart center cardiology for surgical palliation for hypoplastic left heart syndrome or surgical palliation for pulmonary atresia or surgical palliation for severe pulmonary stenosis exclusion criteria: * those who do not meet inclusion criteria

Keywords: hypoxemia palliative neonatal surgery
mindfulness in adolescents with obesity

Conditions: Mindfulness; Usual Care

Summary: the goal of this study is to conduct a single arm open trial to examine the feasibility of a brief, adjunctive mindfulness intervention tailored to the needs of adolescents with severe obesity.

the purpose of this study is to examine whether it is feasible to integrate a brief, adjunctive mindfulness intervention with the standard medical management of obesity in adolescents with severe obesity. mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. mindfulness training enhances one's ability to cope with negative emotions and one's awareness of decision-making processes and internal experiences. the proposed study has two specific aims: 1) to conduct a single arm open trial to examine the feasibility and acceptability of the mindfulness intervention in a sample of 15 adolescents with severe obesity; and 2) to examine the preliminary efficacy of the mindfulness intervention on bmi, emotion regulation, eating and weight-related behaviors, impulsivity, waist circumference, and blood pressure in comparison to the standard of care.

Eligibility criteria:
inclusion criteria: * between the ages of 12 - 17 years * a current patient of our affiliated obesity clinic * have a body mass index (bmi) between 30 and 45 kg/m2. exclusion criteria: * have a known genetic cause of obesity * have been diagnosed with a severe intellectual or learning disability * have been diagnosed with an autism spectrum disorder or current psychosis * are taking a medication intended to reduce body weight
safety and efficacy of s-8184 in treatment of locally advanced, metastatic, or recurrent tcc of the urothelium

Conditions: Urologic Neoplasms

Summary: phase iia, multicenter, dose escalation study evaluating the safety and efficacy of weekly s-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell carcinoma of the urothelium.

the goals of this study are to determine the objective response rate, to determine time to disease progression, duration of response, and survival, and to identify the maximum tolerated weekly dose and principal toxicities of s-8184 in this patient population.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of transitional cell carcinoma of the urothelium including renal pelvis, ureter, bladder, or urethra * locally advanced with lymph node disease(unresectable t3-4, n+, m0); metastatic (t any, n any, mi); or locally recurrent disease following initial definitive therapy * one and only one prior systemic cytotoxic chemotherapy regimen (note that intravesical treatments are not included in the definition of systemic cytotoxic chemotherapy) * failure of first line systemic chemotherapy with a platinum-containing combination regimen consisting of mvac or cisplatin/gemcitabine with cisplatin dosed at 60 mg/m2 or higher per cycle * adult (18 years of age or older) patients * adequate hematologic function (anc greater than 1500 cells/mm3 and platelets greater than 100,000/mm3) * serum creatinine less than 2.0 mg/dl * total bilirubin less than 1.5 mg/dl; sgot and sgpt less than 3 times the upper limit of institutional normal values * ecog performance status of 0 - 2 * bidimensional measurable disease * patients who have signed an irb / ethics committee approved informed consent * life expectancy at least 12 weeks * patient has fully recovered from any previous surgery (at least 4 weeks since major surgery) * patient has a negative pregnancy test prior to study entry if premenopausal. (patients of child bearing potential must use a medically effective form of contraception during the treatment.) exclusion criteria: * patients who have received any taxane-containing preparation including taxol (paclitaxel) or taxotere (docetaxel) * patients with intracranial metastases * females who are pregnant or lactating * patients with peripheral neuropathy nci-ctc grade 2 or greater * patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal therapy within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of study entry * patients who have had an investigational agent within 4 weeks of study entry * patients receiving concurrent anticonvulsants known to induce p450 isoenzymes

Keywords: locally advanced, metastatic, or recurrent transitional cell carcinoma of the urothelium
the correlation between aqp-4 ab and the visual function of patients with demyelinating on at onset

Conditions: Optic Neuritis

Summary: to evaluate the optical coherence tomography (oct), visual field (vf), visual evoked po-tential(vep) characteristics between neuromyelitis optica- related optic neuritis (nmosd-on) and multiple sclerosis- related on (ms-on) in a chinese cohort.

patients were sub-divided into an aqp4 seropositive group and an aqp4 seronegative group, according to the results of the aqp4-ab test. all patients with complete medical histories underwent routine neurological examinations, brain mris, and ophthalmological examinations, including best corrected visual acuity (bcva), intraocular pressure, slit lamp and fundus examination, vf and vep, laboratory testing, including blood routine, hiv hbv hcv syphilis, mitochondrial dna sequencing, and a profile of autoantibodies, including antinuclear antibody (ana), extractable nuclear antigen antibodies (ssa/ssb), rheumatoid factor (rf), anticardiolipin antibodies (aca), and antithyroglobulin antibody.

Eligibility criteria:
inclusion criteria: * optic neuritis patients exclusion criteria: * the presence of significant refractive errors (3d of spherical equivalent refraction or 2d of astigmatism), intraocular pressure of 21 mmhg or higher, systemic conditions that could affect the visual system, and a history of ocular trauma or concomitant ocular diseases, including a history of media opacification, ocular pathologies affecting the cornea, lens, retinal disease, glaucoma, or laser therapy. all patients in the study groups had an episode of on more than six months before the study inclusion time point.
the effect of deep versus moderate muscle relaxants in men during and after robotic surgery for prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine if there is a difference in intra-abdominal pressure which surgeons use during surgery and post-surgery pain in men who undergo robotic prostate surgery with deep neuromuscular blockade (nmb), compared with moderate nmb.


Eligibility criteria:
inclusion criteria: * adult patients under the age of 80 * american society of anesthesiologists physical status 1, 2, 3. * elective robotic prostatectomy * patient undergoing surgery at josie robertson surgical center exclusion criteria: * age younger than 18 * inability to provide informed consent * allergy to rocuronium, sugammadex, midazolam, propofol, fentanyl, lidocaine, mannitol (iv acetaeminophen), iv acetaminophen, ketorolac, morphine, hydromorphone, dexamethasone, zofran, benadryl, compazine * neuromuscular disease * any patient with previous abdominal surgery less than or equal to 20 years prior to scheduled surgery date * patients with bmi\>35 * severe renal impairment (creatinine clearance \< 30 ml/min) * patient receiving toremifene or any history of receiving toremifene * chronic pain patients * patients receiving suboxone * patients receiving succinylcholine

Keywords: prostate cancer robotic surgery muscle relaxants neuromuscular blockade 18-408 memorial sloan kettering cancer center
does a patient education video augment pelvic floor physical therapy compliance?

Conditions: Patient Compliance; Pelvic Floor Disorders

Summary: the investigators intend to measure compliance with attending pelvic floor physical therapy (pfpt) in a urogynecology population by randomizing patients to either viewing a four minute educational video or reading a handout explaining the therapy.

patients who have been interviewed, examined, and a plan has been made by the treating physicians in the female pelvic medicine \& reconstructive surgery practice will be invited to participate at the end of the visit if the patient and physician mutually agree that pfpt is the treatment modality to pursue. if she agrees to participate, she will be consented and randomized. if she is randomized to standard counseling, she will be given the standard handout to read. if she is randomized to the intervention, she will receive the standard handout and view the 4-minute educational video on an ipad. at the conclusion of the counseling, patients will be asked if they have any additional questions, and these will be recorded and answered. the patient will also fill out a visual analog scale about how informed she feels regarding pfpt.

Eligibility criteria:
inclusion criteria: * patients who have prescribed pfpt by a treating physician in the female pelvic medicine \& reconstructive surgery practice exclusion criteria: * patients ≤ 18 years old
pharmacogenetic and antidepressant treatment in elderly

Conditions: Depression

Summary: the study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome p450 2d6) of elderly depressed patients. therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.


Eligibility criteria:
inclusion criteria: * current major depressive disorder * antidepressant treatment exclusion criteria: * dextromethorphan contra-indication * other psychiatric disorder * kidney failure * liver failure mini mental state examination (mmse)\<18
immune responses after human subject challenge with sand fly bites

Conditions: Healthy

Summary: sand flies can carry the infection leishmaniasis (a parasite). the purpose of this study is to evaluate the human immune response to uninfected laboratory raised sand fly bites and select from the immune response to sand fly saliva, possible substances to use for a future vaccine to protect against the parasite leishmaniasis.

based on travel history and possible exposure, subjects were entered into one of 2 arms, ph. dubosqui or lu. lutzomyia controlled sand fly repeated feedings. at baseline a pheresis was done to collect baseline cells. subjects received sand fly bites on a q2 week schedule for 2 months followed by a q2 months schedule for one year. they had an option to extend for a late recall feeding at 18 months, when a skin biopsy was performed 48 hours after sand fly bites. currently the study is fully enrolled and all human subject contact is complete. we (laboratory at niaid) are studying the humoral, cellular immune responses using blood samples, and cytokine expression in the skin biopsy samples.

Eligibility criteria:
inclusion criteria: * age 18-50 * plans to remain in dc area for at least one year * willingness to participate in all study procedures * general good health * military health care beneficiary * able to provide informed consent exclusion criteria: * prior travel to geographic areas where leishmania transmitting sand flies are common * positive antibody to sand fly saliva on screening blood test * pregnancy * elevated serum ige * history of chronic medical illness * adult history of treatment requiring anemia * large reactions to insect bites * history of multiple vasovagal reactions to phlebotomy * difficult venous access for phlebotomy * taking medications that could interfere with immune responses

Keywords: sandfly leishmaniasis immune response individuals age 18-50
pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural or peritoneal mesothelioma

Conditions: Mesothelioma

Summary: the purposes of this study are to determine: 1. the safety of pemetrexed plus gemcitabine and any side effects that might be associated with the combination of these two drugs. 2. whether pemetrexed plus gemcitabine can help patients with mesothelioma live longer. 3. whether pemetrexed plus gemcitabine can make the tumor smaller or disappear, and for how long. 4. to see if patients feel better while taking pemetrexed plus gemcitabine.


Eligibility criteria:
inclusion criteria: * diagnosis of mesothelioma that can be treated with chemotherapy * have received no prior chemotherapy for mesothelioma * have at least one measurable lesion * have an adequate performance status * sign an informed consent exclusion criteria: * previous treatment with chemotherapy for mesothelioma * treatment with an investigational drug within the last 30 days, previously completed or withdrawn from this study or any other study investigating pemetrexed * treatment with radiation therapy within the last 4 weeks * brain metastasis that is uncontrolled * active infection or other serious condition
metformin for the treatment of unexplained oligozspermia

Conditions: Infertility

Summary: insulin resistance (ir) in men may be the underlying pathogenesis for metabolic abnormalities and chronic hypospermatogenesis similar to women with polycystic ovarian disease (pcod). infertile men with unexplained infertility and ir may benefit from treatment with metformin.

recently insulin resistance (ir) has been recognized as the underlying pathogenesis of chronic anovulation, hyperandrogenism, and metabolic abnormalities associated with pcod in women. ir could be the underlying pathogenesis of chronic hypospermatogenesis leading to oligospermia and azoospermia associated with other metabolic abnormalities in men. metformin has proven as an effective medication for not only ir but several other aspects of the pcod including reproductive abnormalities. therefore, insulin sensitizers, particularly metformin can be introduced as a pharmaceutical option for unexplained oligozoospermia and azoospermia associated with insulin resistance.

Eligibility criteria:
inclusion criteria: * oligospermia ( \< 10 million per mil-litter ) * normal fsh * high insulin exclusion criteria: * abnormal karyotype * obstructive azoospermia

Keywords: metformin insulin resistance male infertility unexplained oligozspermia clomiphene citrate unexplained azoospermia
pecha kucha method effects on posttraumatic growth and psychological resilience

Conditions: Posttraumatic Growth; Psychological Resilience; Breast Cancer Patients

Summary: this study was planned to investigate the effect of the training given to breast cancer patients receiving chemotherapy with pecha kucha method on posttraumatic growth and psychological resilience.

this study is a randomized controlled trial planned to investigate the effect of the training given to breast cancer patients receiving chemotherapy with the pecha kucha method on posttraumatic growth and psychological resilience.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * at least one course of adjuvant chemotherapy prior to treatment, * literacy * communicable patients * patients who agreed to participate in the study exclusion criteria: * with a psychiatric diagnosis,
prevention of recurrence in depression with drugs and ct

Conditions: Depression

Summary: this study will determine whether the addition of cognitive therapy (ct) to antidepressant medication (adm) enhances treatment for depression. this study will also test whether the addition of ct to adm will prevent recurrences of depression after therapy is over.

it is commonly believed that the combination of adm and psychotherapy is more effective in treating depression than either treatment alone. data indicate that ct enhances the initial effects of adm, but little research has been conducted to determine whether prior exposure to ct prevents the onset of new depressive episodes. this study will determine the effectiveness of adding ct to adm for the treatment of depression. participants are randomly assigned to receive either adm alone or adm plus ct for up to 18 months. remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. at recovery, patients receiving combined treatment discontinue cognitive therapy; all recovered patients are randomized a second time to either maintenance medication or medication withdrawal. patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.

Eligibility criteria:
inclusion criteria: * recurrent or chronic major depressive disorder exclusion criteria: * current diagnosis of psychotic affective disorder * history of nonaffective psychotic disorder * substance dependence last three months requiring detox * schizotypal, antisocial, or borderline personality disorder
effects of low-intensity interval walking with blood flow restriction on functional capacity in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the aim of the study is to evaluate the safety, feasibility and initial efficacy of an interval-based walking training at low speed performed with blood flow restriction (bfr) on gait speed and functional impairments in patients with multiple sclerosis (ms). patients with severe ms will be recruited at outpatient rehabilitation clinics (university hospital of ferrara). eligible participants will be randomized to interval walking training with bfr (the experimental group) or conventional exercise therapy (the control group) according to a blocked-randomization stratified by gender with 1:1 ratio. both groups will receive 12 rehabilitative sessions over 6 weeks, for a 2 sessions/week pattern. the experimental group will undergo interval-based walking training at a slow speed according to a walk:rest ratio of 1:1 for a total of 6 minutes, to be repeated 5 times. blood flow restriction, applied to the proximal thigh, will be set at a maximum of 40% of systolic blood pressure. the control group will be treated with conventional therapy. changes in gait speed, endurance, balance, lower limbs strength and quality of life will be assessed at baseline, at the end of training, and at follow up. the proposed training modality has never been tested in patients with ms and, if the hypotheses were supported by the results, might be a novel tool to improve muscle strength with a positive impact on gait disabilities, balance and quality of life for patients with ms.


Eligibility criteria:
inclusion criteria: * primary and secondary progressive ms patients according to the diagnostic ms criteria revised by polman et al. * male and females, aged 18 to 65 years; * severe gait impairments, defined by an expanded disability status scale (edss) ranging from 5.5 to 6.5; * lack of ms worsening in the previous three months prior to the intervention period; * cognitive functioning to provide informed consent identified by a mini-mental status examination (mmse) score = 24/30. exclusion criteria: * neurologic conditions in addition to ms that may affect motor function and other medical conditions likely to interfere with the ability to complete safely the study protocol, independently from the group assignment; * considerable muscle spasticity, defined by a modified ashworth scale (mas) score \> 3 or contractures that may limit range of motion or function for hip, knee or ankle flexors/extensor; * relapsing of ms-related conditions or changes in drug therapy or any other confounding factor during the study; * rehabilitation treatments or botulinum toxin injections during the three months preceding the start of the study. * intermittent claudication and peripheral artery disease * contraindication to exercise training (e.g., unstable angina, congestive heart failure)

Keywords: mobility exercise therapy blood flow restricted exercise rehabilitation